Bausch & Lomb Corp
Company Profile
Business description
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Contact
520 Applewood Crescent
VaughanONL4K 4B4
CANT: +1 905 695-7700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,500
Stocks News & Analysis
stocks
Ask the analyst: Are markets missing something with CSL?
stocks
This ASX stock’s bubble has well and truly burst
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,218.00 | 10.50 | -0.11% |
CAC 40 | 7,709.81 | 133.23 | -1.70% |
DAX 40 | 24,152.87 | 120.25 | -0.50% |
Dow JONES (US) | 45,418.07 | 135.60 | 0.30% |
FTSE 100 | 9,265.80 | 55.60 | -0.60% |
HKSE | 25,542.52 | 17.60 | 0.07% |
NASDAQ | 21,544.27 | 94.98 | 0.44% |
Nikkei 225 | 42,588.27 | 193.87 | 0.46% |
NZX 50 Index | 12,900.88 | 57.10 | -0.44% |
S&P 500 | 6,465.94 | 26.62 | 0.41% |
S&P/ASX 200 | 8,950.70 | 10.50 | -0.12% |
SSE Composite Index | 3,881.07 | 12.69 | 0.33% |